A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Primary Objective: To document activity of durvalumab immediately following chemoRT in patients undergoing primary tumor surgery with stage II-IV MSS rectal cancer
Patient Population: patients with microsatellite stable (MSS) stages II-IV rectal cancer
Target Accrual: 47 patients
Status: recruiting participants
ClinicalTrials.gov Identifier: NCT03102047
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402